Key facts
- It has raised $13.1M; the latest was Later Stage VC ($4.5M) in Jun 2025.
- Notable investors include Creative Destruction Lab, Google for Startups, MedTech Innovator, European Commission, Almi Invest — 44 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 44 names
- ·Watchlist + deal alerts for Acorai
- ·The full record, as it builds
Funding rounds
No funding rounds for Acorai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Acorai
Developer of a scalable medical device designed for non-invasive cardiac and pulmonary pressure monitoring to improve heart failure management. The company offers accurate and cost-efficient heart failure care using patented technology that leverages a novel combination of sensor technologies and machine learning to enable non-invasive heart failure monitoring, enabling healthcare personnel to adjust medication proactively and reduce both heart failure re-hospitalization and mortality rates.
- Sector
- Healthcare
- HQ
- Helsingborg, Sweden
- Founded
- 2019
- Employees
- 20
- Website
- acorai.com/
- Ownership
- Privately Held (backing)
Acorai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Acorai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Acorai in its N-PORT filings yet. We sweep new filings monthly.